ML-T7

ML-T7 is a selective T-cell immunoglobulin and mucin domain-containing proteins TIM-3/4 inhibitor that targets the FG-CC′ cleft involved in PtdSer and CEACAM1 binding (h/mTIM-3 Kd = 6.98/7.40 μM, hTIM-4 Kd = 11.98 μM). ML-T7 promotes the activity of nature killer (NK) cells, the antigen-presenting capacity of dendric cells (DCs), the survival and antitumor activity of primary CD8+ cytotoxic T lymphocytes (CTLs) and chimeric antigen receptor (CAR) T cells (5-10 μM). ML-T7 exerts antitumor activity and potentiates anti-PD-1 therapy in a spontaneous orthotopic hepatocellular carcinoma (HCC) model in mice in vivo (20 mg/kg, q.o.d. i.p.).